- Congressos
- IMCAS Asia - junho 2025
- IMCAS China - julho 2025
- IMCAS World Congress - janeiro 2026
- Masterclasses
- IMCAS India - novembro 2025
- Congressos
- IMCAS Asia - junho 2025
- IMCAS China - julho 2025
- IMCAS World Congress - janeiro 2026
- Masterclasses
- IMCAS India - novembro 2025

IMCAS Academy

Criar conta

Log-in

Introdução
Programa
Palestrantes
Lista de patrocinadores
Mapa do congresso
Credenciamento

VOLTAR

IMCAS World Congress 2019
Programa

S085

Melasma: change the color of your skin (in collaboration with SMD)

Partner of the session

SMD

Société Marocaine de Dermatologie

Marrocos

Destaque no programa

Sala: Amphi Havane (level 3)
Data: quinta-feira 31 janeiro 2019 de 14:00 às 15:00
Formato: FOCUS SESSION > lectures covering a major topic of the congress

Moderador

Dr Mukta SACHDEV

Dermatologista

Índia

Apresentações desta sessão

Horas	Palestrantes	Título da apresentação	Resumo	Número
14:17	Dr Behrooz KASRAEE	Skin depigmenting agent: what's new (Cysteamine and others)?	Visualizar	78633
14:29	Prof Philippe HUMBERT	Benefits of oral supplementation for melasma		78635
14:41	Prof Desmond J TOBIN	Modulation of skin pigmentation with topicals	Visualizar	71531

Ir para a sala anterior (Amphi Bordeaux (level 3))

Ir para a próxima sessão

Sessões recomendadas

Pigmentation

Melasma

Vitiligo

Cosmeceuticals

Topical therapies

Dr Behrooz KASRAEE

Dermatologista

França

Outro(s) autor(es) :

Skin depigmenting agent: what's new (Cysteamine and others)?

Objectives: Melasma and post-inflammatory hyperpigmentation (PIH) are frequent skin hyperpigmentary disorders which can present therapeutic challenges for the clinician. The therapeutic armamentarium against melasma and PIH is being significantly changed during the past years mainly due to the safety issues regarding the gold standard treatment, hydroquinone followed by its ban in several countries and on the other hand the emerge of depigmenting molecules with a better safety profile into the market.

Introduction: In this presentation, new therapeutic options for melasma and PIH as well as their safety and efficacy profiles will be presented. Some oral and parenteral skin depigmenting agents (e.g. tranexamic acid) as well as biogenic depigmenting compounds (e.g. L-cysteamine) will be discussed.

Results: Cysteamine hydrochloride is known for its potent depigmenting effect since 1960's when Chavin tested it through injecting cysteamine into the black goldfish skin (1). A few years later, different in vivo studies showed the higher depigmenting efficacy of this molecule compared to hydroquinone (2). Superiority to hydroquinone was recently confirmed in vitro (3). However, cysteamine has never been utilizable in human mainly due to the very offensive odor it produced in topical products. Results for a comparative study with Kligman formula will be presented.

Conclusion: Cysteamine is biologically produced in mammalian cells and serves as an intracellular anti-oxidant. This molecule is FDA approved as eye-drops and as an oral medication and has a long history of safety for human use. The anti-mutagenic and anti-carcinogenic effects of cysteamine are previously shown in numerous studies. With its high efficacy and safety profiles, topical cysteamine has a higher benefit/risk ratio compared to hydroquinone and might serve as a new safe and effective skin depigmenting agent for the treatment of hyperpigmentary disorders such as melasma.

Divulgação de informações

Você recebeu algum patrocínio para sua pesquisa neste tema?
Sim
Por favor indique a entidade (pessoa ou empresa): beyond cosmeceuticals SA

Você recebeu algum tipo de honorário, pagamento ou outra forma de compensação por seu trabalho neste estudo?
Sim
Por favor indique a entidade (pessoa ou empresa): beyond cosmeceuticals SA

Você possui relação financeira com alguma entidade que possa competir com os medicamentos, materiais ou instrumentos abordados no seu estudo?
Sim
Por favor indique a entidade (pessoa ou empresa): beyond cosmeceuticals SA

Você detém ou pediu a registro de patente para algum dos instrumentos, medicamentos ou materiais abordados no seu estudo?
Não

Este trabalho foi realizado com o patrocínio de: beyond cosmeceuticals SA

Prof Philippe HUMBERT

Dermatologista

França

Outro(s) autor(es) :

Benefits of oral supplementation for melasma

Prof Desmond J TOBIN

PhD - Investigação

Irlanda

Outro(s) autor(es) :

Modulation of skin pigmentation with topicals

Objectives: The literature is full of reports claiming to describe inhibitors (and more recently stimulators) of melanin synthesis and transfer. This talk will provide understanding of how modulation of skin pigmentation can be approached from several levels in terms of melanin synthesis (amount and subtype), transfer to keratinocytes, distribution within different epidermis strata and ultimate melanin fate. This talk with review our recent work in this area.

Introduction: Melanin is synthesized by melanocytes in the epidermis basal layer, and when transferred to keratinocytes is the key ultraviolet radiation-protective biopolymer responsible for skin pigmentation. However, most melanin is seen only in the proliferative basal layer and only sparsely above this. The latter has been explained (without convincing evidence) as 'melanin degradation' in suprabasal layers. We have recently re-evaluated how melanin is distribution in human epidermis under normal and stress conditions. Our new understanding allows us to reassess how melanin levels can be modulated.

Materials / method: Using skin tissues derived from normal healthy individuals of different skin phototype, and cell cultures derived from these tissues for standard bioscience experimental analysis.

Results: We have recently revisited the need to develop a new generation of safe topical ingredients, with cosmetic and therapeutic potential (vitiligo, Pityriasis alba etc.). We have identified a novel way to modulate the epidermal-melanin unit function, by mimicking a growth factor that stimulates melanogenesis and melanin transfer. Specifically, we have identified small peptide mimics of BMP6, by interrogating the binding site of BMP6 with its receptor. After cytotoxicity assessment in vitro, we have evaluated these in aqueous-soluble and topical form using pigmented human skin equivalents.

Conclusion: Some of these peptides exhibited the ability to increase melanogenesis when topically applied in a 3-D human skin model, and we believe that this technology offers significant benefits over the currently available technology. We are currently investigating whether these molecules may be modified to have the reverse activity on this melanogenesis pathway.

Divulgação de informações

Você recebeu algum patrocínio para sua pesquisa neste tema?
Não

Você recebeu algum tipo de honorário, pagamento ou outra forma de compensação por seu trabalho neste estudo?
Não

Você possui relação financeira com alguma entidade que possa competir com os medicamentos, materiais ou instrumentos abordados no seu estudo?
Não

Você detém ou pediu a registro de patente para algum dos instrumentos, medicamentos ou materiais abordados no seu estudo?
Não

Este trabalho não recebeu nenhum patrocínio direto ou indireto. O mesmo está sob a própria responsabilidade do seu autor.

Você tem alguma dúvida?

Encontre rápido uma resposta na lista de perguntas frequentes

Congressos

IMCAS Asia
IMCAS China
IMCAS World Congress

Sobre

Empresa
Política de privacidade
Informação legal

Academy

Home
Cursos
Webinars
Explore
Blog

Subvenção

Subvenção educacional

Entre em contato

Entre em contato conosco

Nome do usuário /E-mail

Senha

Continuar na conta

Log-in

Esqueci minha senha ? Você já possui uma conta? Assine agora

Mantenha-me conectado

academy.Do_not_have_an_account_yet Assine agora

IMCAS World Congress 2019 Programa

S085

Melasma: change the color of your skin (in collaboration with SMD)

Moderador

Apresentações desta sessão

Sessões recomendadas

IMCAS World Congress 2019
Programa